Replimune REPL 深 沪
已收盘 12-05 16:00:00 美东时间
10.61
+0.080
+0.76%
华盛通- 最 高10.64
- 今 开10.35
- 成交量 109.88万股
- 最 低 10.27
- 昨 收 10.53
- 总市值 8.28亿
- 52周最高 14.7952
- 市盈率 静 --
- 换手率 1.41%
- 52周最低 2.68
- 委 比 46.64%
- 总股本 7805.58万
- 历史最高 54.79
- 量 比 0.50
- 振 幅 3.51%
- 历史最低 2.68
- 每 手 1
- 风险率 2.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多SA Quant ranks Goldman's small-cap stocks with largest short interest
Goldman Sachs analysts last week identified 50 small-cap stocks with the highest short interest as a percentage of market cap, a list that was topped by Anavex Life Sciences (AVXL). The brokerage look...
11-27 04:13
The Short List — Top 10 Most Shorted Stocks Right Now
Here's a look at the top ten most shorted stocks in the market right now, including Wendy's, Lucid and Wolfspeed.
11-27 00:34
Replimune Group Q2 EPS $(0.90) Misses $(0.74) Estimate
Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.74) by 21.46 percent. This is a 32.35 percent decrease over losses of $(0.68) per share from
11-06 21:21
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
Replimune Group announced the acceptance of the BLA resubmission for RP1 for advanced melanoma with a PDUFA target date of April 10, 2026. RP1's Phase 3 trial, IGNYTE-3, continues to enroll patients, with promising data showing an ORR of 44% in acral melanoma and strong responses across multiple NMSC types. RP2's Phase 2/3 REVEAL trial for metastatic uveal melanoma is actively enrolling. The company reported a cash balance of $323.6 million and a...
11-06 13:00
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining mor...
11-03 21:14
BMO Capital Upgrades Replimune Group to Market Perform, Raises Price Target to $11
BMO Capital analyst Evan David Seigerman upgrades Replimune Group (NASDAQ:REPL) from Underperform to Market Perform and raises the price target from $2 to $11.
11-03 18:37
期权扫描 | 高通期权成交放量超8倍，一CALL单飙升2680%；ASST获多张CALL单押注看涨
高通推出人工智能芯片，股价飙升！期权成交放量超8倍，一CALL单飙升2680%；ASST获多张CALL单押注看涨至3美元>>
10-28 17:10
美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
10-28 10:08
Novartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain
Novartis' Cosentyx Phase 3 REPLENISH trial for polymyalgia rheumatica met primary and secondary endpoints, showing significant sustained remission.
10-23 02:35
